Compare OFG & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFG | TWST |
|---|---|---|
| Founded | 1964 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | N/A | 2018 |
| Metric | OFG | TWST |
|---|---|---|
| Price | $43.07 | $31.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $45.75 | $44.88 |
| AVG Volume (30 Days) | 249.6K | ★ 1.4M |
| Earning Date | 01-21-2026 | 02-02-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | ★ 6.55 | N/A |
| EPS | ★ 4.40 | N/A |
| Revenue | ★ $624,004,000.00 | $376,572,000.00 |
| Revenue This Year | N/A | $15.19 |
| Revenue Next Year | $1.09 | $15.10 |
| P/E Ratio | $9.69 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $33.15 | $23.30 |
| 52 Week High | $46.11 | $55.33 |
| Indicator | OFG | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 69.21 | 54.42 |
| Support Level | $41.88 | $30.21 |
| Resistance Level | $42.67 | $33.31 |
| Average True Range (ATR) | 0.72 | 1.81 |
| MACD | 0.29 | 0.07 |
| Stochastic Oscillator | 94.48 | 62.68 |
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.